Phase 2 Multiple Sclerosis Trial, Recruiting NCT06463743 Sponsor: State University of New York at Buffalo Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Phase 2 Multiple Sclerosis Trial, Recruiting

NCT06463743
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 55 and 75 years old
  • You have been diagnosed with Multiple Sclerosis (MS) based on specific diagnostic guidelines (confirm with trial site)
  • Your MS has been stable for the last 2 years, meaning no relapses and no new activity shown on brain scans, as confirmed by your MS doctor
  • Your level of disability is below a certain threshold on a standard MS disability scale (confirm with trial site)

Who may not be able to join:

  • You are unable to have MRI scans (for example, due to a pacemaker or severe claustrophobia)
  • You are unable to take part in the study for the full duration of the trial
  • You have diabetes or a cardiovascular (heart or blood vessel) condition that is not well controlled
  • You are unable to give your own informed consent to participate

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 7168295037

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
State University of New York at Buffalo
Registry
ClinicalTrials.gov
Start date
24 September 2025
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.; Percent change in N-Acetyl Aspartate (NAA) in the cortex over 9 months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov